1 BTC
=
- USD
Atrium Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Market Statistics
Trading Metrics
How to Buy RNA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy RNA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesInvestor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the transactions.
Monteverde & Associates PC, a class action securities firm, is investigating four proposed mergers: The Brand House Collective's sale to Bed Bath & Beyond, Avidity Biosciences' acquisition by Novartis for $72 per share, NorthWestern Energy Group's sale to Black Hills Corp, and Two Harbors Investment Corp's merger with UWM Holdings Corporation. The firm is seeking shareholders with concerns about these transactions ahead of upcoming shareholder votes.
Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.